EAM
YMAB

Erste Asset Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Erste Asset Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,000
Closed -$169K – 572
2021
Q4 		$169K Hold
10,000
– – ﹤0.01% 498
2021
Q3 		$279K Hold
10,000
– – 0.01% 459
2021
Q2 		$339K Hold
10,000
– – 0.01% 445
2021
Q1 		$296K Hold
10,000
– – 0.01% 428
2020
Q4 		$504K Buy
+10,000
New +$463K 0.01% 385

Other funds holding YMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Erste Asset Management's YMAB Position: Q1 2022 in Review

Erste Asset Management sold out of Y-mAbs Therapeutics (YMAB) in Q1 2022, closing a stake of 10,000 shares — an estimated $169K sold.

Erste Asset Management first reported a position in YMAB in Q4 2020 and held it in 5 quarters. The position peaked at $504K in Q4 2020. 88 funds tracked by Wall St. Rank hold YMAB as of Q1 2022.

  • Erste Asset Management reported no remaining Y-mAbs Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Erste Asset Management sold 10,000 Y-mAbs Therapeutics shares in Q1 2022, an estimated $169K.
  • Erste Asset Management first reported a position in Y-mAbs Therapeutics in Q4 2020 and held it in 5 quarters.
  • Erste Asset Management's Y-mAbs Therapeutics position peaked at $504K in Q4 2020.
  • 88 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2022.

Based on Erste Asset Management's 13F filing for Q1 2022, filed 25 Nov 2024.